John H. Parrish

President & CEO

Mr. Parrish is a founder, Director, President and Chief Executive Officer of BioVascular, Inc. He has founded and been founding CEO of two medical device and four pharmaceutical companies, and has over 30 years of medical industry experience. He was previously President/CEO of Angiosyn, Inc. (acquired by Pfizer), Optobionics Corp. (privately held), Valley Forge Pharmaceuticals (privately held), ISTA Pharmaceuticals (publicly held), Intramed Labs. (publicly held), and Vitalmetrics, Inc. (publicly held). Previously he had served IVAC Corp. and Baxter Healthcare in various management positions. He is a member of the Board of Directors of Cardioptics Corp., Valley Forge Pharmaceuticals, and the Discovery Eye Foundation at University of California, Irvine. He holds a B.S. degree in Biology/Chemistry from Wake Forest University, where he served on the schools Board of Visitors.



Paul F. Glidden, PhD

Vice President, Development

Dr. Glidden is a founder, Director and Vice President of Development of BioVascular, Inc.  He was previously Vice President, Development of Angiosyn, Inc.  In this position, Dr. Glidden was responsible for all Non-clinical, Manufacturing, Regulatory, Quality and Clinical aspects of the T2-TrpRS project.  This project was acquired by Pfizer in January 2005 where it continues to be developed for treatment of Age-related Macular Degeneration.  Prior to this position, Dr. Glidden was Director of Pharmacology and Toxicology at ISTA Pharmaceuticals. While at ISTA, his work on the NDA for Vitrase, a biologic compound injected into the vitreous cavity of the eye to dissolve a vitreous hemorrhage.  From 1989 to 2000, Dr. Glidden was at Alpha Therapeutics developing new chemical entities for cardiovascular therapies, including critical limb ischemia and intermittent claudication, new molecular entities for the treatment of non-Hodgkin’s lymphoma, and blood-derived products for use in surgical maneuvers or as replacement therapy as Manager of Pharmacology.  Dr. Glidden holds a B.S. degree in Biochemistry and Biophysics from Oregon State University and a Ph.D. in Pharmacology and Toxicology from University of California, Irvine.




Alison J. Pilgrim, MD, PhD

Chief Medical Officer, Vice President of Clinical Research & Regulatory Affairs

Dr. Pilgrim has extensive experience in leading the global development of drugs  in a wide range of therapeutic areas including cardiology, neurology, psychiatry and inflammation. While at Glaxo she led the clinical program for Imitrex from phase 2-4 and through a series of line extensions. At Sanofi she oversaw the global approval of Plavix and initiated the major megatrials which were key to the successful commercialization of the drug. Dr Pilgrim has experience of leading drug development within both large integrated pharmaceutical companies, such as Glaxo, Sanofi and DuPont and within smaller and virtual companies including Elan, Avera and CoLucid. As a clinical pharmacologist at Beecham Pharmaceuticals she was responsible for a wide range of early clinical studies, including first-in-man, pharmacokinetics and efficacy modeling in healthy subjects. Dr Pilgrim trained as a scientist and physician at Oxford University in the UK, qualifying as a physician and gaining a doctorate in development neurobiology.



Christopher M. Bussineau, PhD

Vice President of Pharmaceutical Operations

Dr. Bussineau was previously Vice President and General Manager for Cambrex Bio Science Baltimore, a contract development and manufacturing business serving the biotechnology industry. Prior to this position, Dr. Bussineau was Senior Director of Technical Operations for Chiron Corporation’s Biopharmaceutical Division. While at Chiron, he held positions of increasing scientific and managerial responsibility in process development as well as clinical and commercial manufacturing that encompassed strategic planning, facility design, technology transfer, validation, regulatory submissions, quality and safety compliance, and customer relations. Dr. Bussineau holds a PhD in Chemical Engineering from Rice University and a BA in Chemistry (biochem emphasis) from University of California, San Diego.


Website design: Evenayr Graphics, Portland Oregon,